May 20 Respiratory drugs specialist Vectura Group Plc reported a bigger-than-expected jump in full-year revenue as it raked in higher royalty payments and licensing revenue.
The company, which develops and markets drugs for illnesses such as asthma and chronic obstructive pulmonary disease, said revenue rose to 58 million pounds ($89.8 million) in the year ended March 31 from 36.5 million pounds a year earlier.
16:37 Fitbit acquires software assets from rival Pebble10
10:05 JPMorgan, HSBC, Credit Agricole Fined $521 Million Over Euribor16
06:10 Sources: Carlos Gomez, Rangers agree on 1-year, $11.5 million deal16
22:35 Bryce Harper's request for record $400 million deal too much for Nationals: report3